Cooley advised Lantheus Holdings (Nasdaq: LNTH), a radiopharmaceutical-focused company committed to enabling clinicians to find, fight and follow disease to deliver better patient outcomes, on its definitive agreement to acquire Evergreen Theragnostics. Under the terms of the agreement, Lantheus will pay an upfront amount of $250 million in cash at closing and up to $752.5 million in development and sales milestones related to OCTEVY, a registrational-stage diagnostic imaging agent, and Evergreen’s clinical and preclinical pipeline. The transaction has been approved by the boards of directors of both companies and is expected to close in the second half of 2025, subject to customary closing conditions, including regulatory clearances.
Lantheus to Acquire Evergreen Theragnostics for up to $1 Billion